Stoke Therapeutics, Inc. (STOK) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Stoke Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:04.680 Good afternoon and welcome to Stoke Therapeutics' second quarter 2025 conference call. 00:00:04.680 -- 00:00:07.800 I'm Tommy Leggett, chief financial officer at Stoke. 00:00:07.800 -- 00:00:12.500 Joining me for prepared remarks are Ian Smith, our interim chief executive officer, Dr. 00:00:12.500 -- 00:00:14.880 Barry Tico, chief medical officer, and Dr. 00:00:14.880 -- 00:00:18.000 Kimberly Parkerson, head of neurology clinical development. 00:00:18.000 -- 00:00:22.500 In addition, Jason Hoyt, our chief patient officer, will participate in Q&A. 00:00:22.500 -- 00:00:27.020 As a reminder, today's webcast slides are available in the investor section of our website. 00:00:27.020 -- 00:00:31.800 This webcast is being recorded and will be available for replay later today. 00:00:31.800 -- 00:00:36.080 Before we begin, please note that today's discussion includes forward-looking statements. 00:00:36.080 -- 00:00:40.540 These are subject to risks and uncertainties, and actual results may differ materially. 00:00:40.540 -- 00:00:43.720 Please refer to the filings of the SEC for additional information. 00:00:43.720 -- 00:00:47.200 With that, I'll turn the call over to Ian. 00:00:47.200 -- 00:00:48.260 Welcome, everyone, 00:00:48.260 -- 00:00:52.440 and thank you for joining us today. I've been working with Stoke Therapeutics for two 00:00:52.440 -- 00:00:55.600 years as a director and advisor, more recently as the CEO. 00:00:55.600 -- 00:01:00.220 It has been a great opportunity to get to know the team, the medicines, and the disease 00:01:00.220 -- 00:01:03.960 areas, and to support the company through this growth period. 00:01:03.960 -- 00:01:08.580 The key priority is obviously Dravet syndrome and Zoriba-Nursen, as we work to deliver 00...